New technique generates rod photoreceptors that integrate into the retina and brain.
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors. The findings advance efforts toward regenerative therapies for blinding diseases such as age-related macular degeneration and retinitis pigmentosa. A report of the findings appears online today in Nature. NEI is part of the National Institutes of Health.
“This is the first report of scientists reprogramming Müller glia to become functional rod photoreceptors in the mammalian retina,” said Thomas N. Greenwell, Ph.D., NEI program director for retinal neuroscience. “Rods allow us to see in low light, but they may also help preserve cone photoreceptors, which are important for color vision and high visual acuity. Cones tend to die in later-stage eye diseases. If rods can be regenerated from inside the eye, this might be a strategy for treating diseases of the eye that affect photoreceptors.”
Photoreceptors are light-sensitive cells in the retina in the back of the eye that signal the brain when activated. In mammals, including mice and humans, photoreceptors fail to regenerate on their own. Like most neurons, once mature they don’t divide.
Scientists have long studied the regenerative potential of Müller glia because in other species, such as zebrafish, they divide in response to injury and can turn into photoreceptors and other retinal neurons. The zebrafish can thus regain vision after severe retinal injury. In the lab, however, scientists can coax mammalian Müller glia to behave more like they do in the fish. But it requires injuring the tissue.
“From a practical standpoint, if you’re trying to regenerate the retina to restore a person’s vision, it is counterproductive to injure it first to activate the Müller glia,” said Bo Chen, Ph.D., associate professor of ophthalmology and director of the Ocular Stem Cell Program at the Icahn School of Medicine at Mount Sinai, New York.
“We wanted to see if we could program Müller glia to become rod photoreceptors in a living mouse without having to injure its retina,” said Chen, the study’s lead investigator.
In the first phase of a two-stage reprogramming process Chen’s team spurred Müller glia in normal mice to divide by injecting their eyes with a gene to turn on a protein called beta-catenin. Weeks later, they injected the mice’s eyes with factors that encouraged the newly divided cells to develop into rod photoreceptors.
The researchers used microscopy to visually track the newly formed cells. They found that the newly formed rod photoreceptors looked structurally no different from real photoreceptors. In addition, synaptic structures that allow the rods to communicate with other types of neurons within the retina had also formed. To determine whether the Müller glia-derived rod photoreceptors were functional, they tested the treatment in mice with congenital blindness, which meant that they were born without functional rod photoreceptors.
In the treated mice that were born blind, Müller glia-derived rods developed just as effectively as they had in normal mice. Functionally, they confirmed that the newly formed rods were communicating with other types of retinal neurons across synapses. Furthermore, light responses recorded from retinal ganglion cells — neurons that carry signals from photoreceptors to the brain — and measurements of brain activity confirmed that the newly-formed rods were in fact integrating in the visual pathway circuitry, from the retina to the primary visual cortex in the brain.
Chen’s lab is conducting behavioral studies to determine whether the mice have regained the ability to perform visual tasks such as a water maze task. Chen also plans to see if the technique works on cultured human retinal tissue.
The Latest on: Congenital blindness
via Google News
The Latest on: Congenital blindness
- Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right)on June 25, 2020 at 8:11 am
In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.
- Gene therapy and CRISPR strategies for curing blindnesson June 25, 2020 at 6:31 am
In a piece originally published on The Conversation, Hemant Khanna, PhD, comments on recent studies that use CRISPR to treat diseases that cause blindness and explains why the eye is an ideal organ ...
- UB vision research contributes to a rethinking of what leads to a rare, hereditary disorder causing blindnesson June 24, 2020 at 7:51 am
A series of papers published by vision researchers is revealing important new information about the possible cause of a condition that underlies a rare form of irreversible blindness in young children ...
- Researcher's work contributes to a rethinking of what leads to a rare disorder causing blindnesson June 24, 2020 at 7:12 am
A series of papers published recently by two teams of vision researchers at the University at Buffalo and the University of Alabama at Birmingham (UAB) is revealing important new information about the ...
- Eye exams for babies: Why they’re importanton June 19, 2020 at 10:05 pm
Eye screening is a critical part of the early well-child examination. In this report by SADE OGUNTOLA, experts say that early detection of ...
- 30 Years Ago, Romania Deprived Thousands of Babies of Human Contacton June 18, 2020 at 6:53 am
F or his first three years of life, Izidor lived at the hospital. The dark-eyed, black-haired boy, born June 20, 1980, had been abandoned when he was a few weeks old. The reason w ...
- Like slavery, there are some (such as my daughter) whom the law treats as less than fully humanon June 14, 2020 at 5:27 pm
Over recent days, reports have appeared of those with learning disabilities in hospitals being assigned Do Not Resuscitate (DNR) notices - simply on the grounds of their disability.
- Researchers question the mechanism of retinitis pigmentosaon June 11, 2020 at 9:24 pm
Researchers who made a knock-in mouse-model of the genetic disorder retinitis pigmentosa 59, or RP59, expected to see retinal degeneration and retinal thinning. As reported in the journal Cells, they ...
- How an Israeli web service, a bong-like insulin device and a Bay Area deal led this Peninsula biotech to attack a childhood diseaseon June 11, 2020 at 1:02 pm
Even in the meandering world of drug development, Rezolute Inc.'s route is unusual. It includes the experience of Elam developing Exubera, an insulin powder developed at Nektar Therapeutics Inc.
via Bing News